B regulatory cells are increased in hypercholesterolaemic mice and protect from lesion development via IL-10

Summary

Whilst innate B1-B cells are atheroprotective, adaptive B2-B cells are considered pro-atherogenic. Different subsets of B regulatory cells (Breg) have been described. In experimental arthritis and lupus-like disease, Breg are contained within the CD21^hiCD23^hiCD24^hi B cell pool. The existence and role of Breg in vascular disease is not known. We sought to investigate the existence, identity and location of Breg in vascular disease. The representation of B2-B cell subsets in the spleens and lymph nodes (LNs) of Apolipoprotein E^-/- (ApoE^-/-) mice compared to controls was characterised by flow cytometry. Additionally, we utilised a model of neointima formation based on the placement of a perivascular collar around the carotid artery in ApoE^-/- mice to ascertain whether B cells and B cell subsets confer protection against lesion development. Adoptive transfer of B cells was performed from wild type or genetically modified mice. We showed that CD21^hiCD23^hiCD24^hi B cells are unexpectedly increased in the draining LNs of ApoE^-/- mice. Adoptive transfer of LN-derived B2-B cells or purified CD21^hiCD23^hiCD24^hi B cells to syngeneic mice reduced lesion size and inflammation without changing serum cholesterol levels. Follicular B2-B cells did not confer protection. IL-10 blockade or transfer of IL10-deficient B cells prevented LN-derived B cell-mediated protection. This is the first identification of a specific LN-derived B2-Breg subset that confers IL-10 mediated protection from neointima formation. This may open the way for immune modulatory approaches in cardiovascular disease.

Keywords

Immunity - B regulatory cells - interleukins - atherosclerosis - vascular disease

^* The authors contributed equally to the paper.

• References

• 1 Buono C, Binder C, Stavrakis G. et al. T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses. Proc Natl Acad Sci USA 2005; 102: 1596-1601.
• 2 Ait-Oufella H, Salomon BL, Potteaux S. et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 2006; 12: 178-180.
• 3 Ait-Oufella H, Herbin O, Bouaziz JD. et al. B cell depletion reduces the development of atherosclerosis in mice. J Exp Med 2010; 207: 1579-1587.
• 4 Kyaw T, Tay C, Khan A. et al. Conventional B2 B cell depletion ameliorates whereas its adoptive transfer aggravates atherosclerosis. J Immunol 2010; 185: 4410-4419.
• 5 Sasaki Y, Casola S, Kutok JL. et al. TNF family member B cell-activating factor (BAFF) receptor-dependent and -independent roles for BAFF in B cell physiology. J Immunol 2004; 173: 2245-2252.
• 6 Kyaw T, Tay C, Hosseini H. et al. Depletion of B2 but not B1a B cells in BAFF receptor-deficient ApoE mice attenuates atherosclerosis by potently ameliorating arterial inflammation. PloS one 2012; 7: e29371.
• 7 Sage AP, Tsiantoulas D, Baker L. et al. BAFF receptor deficiency reduces the development of atherosclerosis in mice--brief report. Arterioscler Thromb Vasc Biol 2012; 32: 1573-1576.
• 8 Kyaw T, Cui P, Tay C. et al. BAFF receptor mAb treatment ameliorates development and progression of atherosclerosis in hyperlipidemic ApoE(-/-) mice. PloS one 2013; 8: e60430.
• 9 Major A, Fazio S, Linton M. B-lymphocyte deficiency increases atherosclerosis in LDL receptor-null mice. Arterioscler Thromb Vasc Biol 2002; 22: 1892-1898.
• 10 Caligiuri G, Nicoletti A, Poirier B. et al. Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J Clin Invest 2002; 109: 745-753.
• 11 Doran AC, Lipinski MJ, Oldham SN. et al. B-cell aortic homing and atheroprotection depend on Id3. Circ Res 2012; 110: e1-12.
• 12 Gjurich BN, Taghavie-Moghadam PL, Ley K. et al. L-selectin deficiency decreases aortic B1a and Breg subsets and promotes atherosclerosis. Thromb Hae-most 2014; 112: 803-811.
• 13 Dimayuga P, Cercek B, Oguchi S. et al. Inhibitory effect on arterial injury-induced neointimal formation by adoptive B-cell transfer in Rag-1 knockout mice. Arterioscler Thromb Vasc Biol 2002; 22: 644-649.
• 14 Hayakawa K, Hardy RR, Herzenberg LA. et al. Progenitors for Ly-1 B cells are distinct from progenitors for other B cells. J Exp Med 1985; 161: 1554-1568.
• 15 Kyaw T, Tay C, Krishnamurthi S. et al. B1a B lymphocytes are atheroprotective by secreting natural IgM that increases IgM deposits and reduces necrotic cores in atherosclerotic lesions. Circ Res 2011; 109: 830-840.
• 16 Shaw PX, Hörkkö S, Chang MK. et al. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest 2000; 105: 1731-1740.
• 17 Lewis MJ, Malik TH, Ehrenstein MR. et al. Immunoglobulin M is required for protection against atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2009; 120: 417-426.
• 18 Mauri C, Gray D, Mushtaq N. et al. Prevention of arthritis by interleukin 10-producing B cells. J Exp Med 2003; 197: 489-501.
• 19 Evans JG, Chavez-Rueda KA, Eddaoudi A. et al. Novel suppressive function of transitional 2 B cells in experimental arthritis. J Immunol 2007; 178: 7868-7878.
• 20 Matsushita T, Yanaba K, Bouaziz J-D. et al. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest 2008; 118: 3420-3430.
• 21 Rosser EC, Oleinika K, Tonon S. et al. Regulatory B cells are induced by gut microbiota-driven interleukin-1beta and interleukin-6 production. Nat Med 2014; 20: 1334-1339.
• 22 Chyu KY, Dimayuga P, Zhu J. et al. Decreased neointimal thickening after arterial wall injury in inducible nitric oxide synthase knockout mice. Circ Res 1999; 85: 1192-1198.
• 23 Asseman C, Mauze S, Leach MW. et al. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 1999; 190: 995-1004.
• 24 Cole JE, Navin TJ, Cross AJ. et al. Unexpected protective role for Toll-like receptor 3 in the arterial wall. Proc Natl Acad Sci USA 2011; 108: 2372-2377.
• 25 Meyer-Bahlburg A, Andrews SF, Yu KO. et al. Characterisation of a late transitional B cell population highly sensitive to BAFF-mediated homeostatic proliferation. J Exp Med 2008; 205: 155-168.
• 26 Blair PA, Chavez-Rueda KA, Evans JG. et al. Selective targeting of B cells with agonistic anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like B cells and for the suppression of lupus in MRL/lpr mice. J Immunol 2009; 182: 3492-3502.
• 27 Angeli V, Llodrá J, Rong JX. et al. Dyslipidemia associated with atherosclerotic disease systemically alters dendritic cell mobilisation. Immunity 2004; 21: 561-574.
• 28 Binder CJ, Hartvigsen K, Chang M-K. et al. IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J Clin Invest 2004; 114: 427-437.
• 29 Mizoguchi A, Mizoguchi E, Takedatsu H. et al. Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity 2002; 16: 219-230.
• 30 Srivastava B, Quinn 3rd WJ, Hazard K. et al. Characterisation of marginal zone B cell precursors. J Exp Med 2005; 202: 1225-1234.
• 31 Grammer AC, Bergman MC, Miura Y. et al. The CD40 ligand expressed by human B cells costimulates B cell responses. J Immunol 1995; 154: 4996-5010.
• 32 Mallat Z, Besnard S, Duriez M. et al. Protective role of interleukin-10 in atherosclerosis. Circ Res 1999; 85: e17-24.
• 33 Caligiuri G, Rudling M, Ollivier V. et al. Interleukin-10 deficiency increases atherosclerosis, thrombosis, and low-density lipoproteins in apolipoprotein E knockout mice. Mol Med 2003; 9: 10-17.
• 34 Zimmerman MA, Reznikov LL, Raeburn CD. et al. Interleukin-10 attenuates the response to vascular injury. J Surg Res 2004; 121: 206-213.
• 35 Mazighi M. IL-10 inhibits vascular smooth muscle cell activation in vitro and in vivo. Am J Physiol Heart Circ Physiol 2004; 287: H866-H871.
• 36 Eefting D, Schepers A, De Vries MR. et al. The effect of interleukin-10 knockout and overexpression on neointima formation in hypercholesterolemic APOE*3-Leiden mice. Atherosclerosis 2007; 193: 335-342.
• 37 Mauri C, Bosma A. Immune Regulatory Function of B Cells. Ann Rev Immunol. 2012 30. null.
• 38 Mallat Z, Gojova A, Brun V. et al. Induction of a regulatory T cell type 1 response reduces the development of atherosclerosis in apolipoprotein E-knockout mice. Circulation 2003; 108: 1232-1237.
• 39 Lipinski MJ, Perry HM, Doran AC. et al. Comment on “Conventional B2 B cell depletion ameliorates whereas its adoptive transfer aggravates atherosclerosis”. J Immunol. 2011 186. 4; author reply 6.
• 40 Pillai S, Cariappa A. The follicular versus marginal zone B lymphocyte cell fate decision. Nat Rev Immunol 2009; 9: 767-777.
• 41 Yoshizaki A, Miyagaki T, DiLillo DJ. et al. Regulatory B cells control T-cell auto-immunity through IL-21-dependent cognate interactions. Nature 2012; 491: 264-268.
• 42 Blair PA, Noreña LY, Flores-Borja F. et al. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity 2010; 32: 129-140.